RxDoctor Payments Data

Youn Jea Kim, NP

Family · Buffalo, NYNPI 1376908442

Payments from drug & device makers

$11,512in general payments, 2019–2025

Across 443 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Novartis$1K
  • Regeneron Healthcare Solutions, Inc.$925
  • Johnson & Johnson$840
  • Sun Pharmaceutical Industries Inc.$797
  • AbbVie$784
  • plus $5K from 19 others

What the payments were for

  • Food & beverage$11,13297%
  • Education$3803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,512 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$224,342
Medicare patients
226
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab60$236,509
Humira(Cf) PenAdalimumab13$172,969
Cosentyx Sensoready (2 Pens)Secukinumab12$128,319
OtezlaApremilast11$52,102
VtamaTapinarof29$44,979
Betamethasone Dipropionate298$26,226
Triamcinolone Acetonide768$14,037
Tretinoin243$12,565
Brimonidine Tartrate25$11,419
Imiquimod332$11,284
Tacrolimus76$10,913
JubliaEfinaconazole11$10,668
Metronidazole198$9,976
Ammonium Lactate292$7,888
Ketoconazole418$6,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$421$52,10211 claims
Dermavant Sciences, Inc.Vtama$587$44,97929 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$37$10,66811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →